What is the appropriate influenza B vaccine dose and administration method for a patient who is post‑splenectomy and has hemophilia?

Post‑splenectomy Hib and Influenza Vaccination in a Patient with Hemophilia

Bold Recommendation: Give 1 dose of Hib conjugate vaccine 0.5 mL IM now (if unimmunized as an adult or >59 months), and give annual inactivated influenza vaccine 0.5 mL IM; avoid live intranasal influenza vaccine. 1, 2

What to give and how (prioritizing morbidity, mortality, and quality of life)

• Haemophilus influenzae type b (Hib)

  • Adults and children >59 months with asplenia who are unimmunized: 1 dose Hib conjugate vaccine, 0.5 mL IM, one time only. This reduces risk of life‑threatening OPSI from encapsulated organisms, directly impacting mortality/QOL 1.
  • If splenectomy is elective and patient ≥15 months and unimmunized: give 1 dose at least 14 days pre‑op when feasible; if already post‑op, give now 1.

• Seasonal Influenza (includes type B components)

  • Use an inactivated or recombinant influenza vaccine: 0.5 mL IM annually (IIV or RIV). Avoid LAIV (intranasal live) due to immunocompromise/asplenia risk considerations and inferior safety profile in these contexts 2, 3, 4.
  • Recombinant (egg‑free) Flublok is an FDA‑approved option for ≥9 years: 0.5 mL IM single dose annually 5.

Hemophilia-specific administration to minimize bleeding

• Route: Intramuscular is acceptable; use a fine needle (e.g., 23–25G), apply firm pressure to site for ≥2 minutes without rubbing; schedule shortly after factor replacement or emicizumab dose when applicable to reduce hematoma risk. These IM precautions are supported for anticoagulated/impaired hemostasis populations and are standard hemophilia practice to preserve QOL and avoid morbidity 3.
• Sites: Prefer deltoid if muscle mass adequate; alternate thigh if needed.

Avoid and common pitfalls

• Do NOT use live attenuated intranasal influenza vaccine (LAIV) in this patient; use inactivated/recombinant IM vaccines only 2, 4.
• Do NOT defer Hib in asplenic adults: a single IM dose is indicated if unimmunized; missing it increases OPSI mortality risk 1.
• Ensure annual influenza vaccination; lapses increase hospitalization and death risk from influenza (including type B) in asplenia 2, 3.

Brief rationale and evidence hierarchy

• Highest-quality/most recent guideline for Hib in asplenia: ACIP 2014—1 dose for unimmunized asplenic adults and >59 months; pre‑splenectomy if elective 1.
• Influenza: ACIP recommends annual IM inactivated/recombinant vaccine and avoidance of LAIV in at‑risk groups; dosing 0.5 mL IM 2. FDA label specifies Flublok 0.5 mL IM for ≥9 years 5.
• Administration safety with bleeding risk: IM acceptable with fine needle and firm pressure; extrapolated from guideline statements and standard practice to prevent injection hematoma, minimizing morbidity 3.

Practical one-page order set

• Hib (if adult/unimmunized or >59 months without Hib after 14 months):
  • Hiberix/ActHIB/PedvaxHIB 0.5 mL IM x1 today 1.
• Influenza (annually, any season now or upcoming):
  • IIV4 or RIV4 (e.g., Flublok) 0.5 mL IM x1; repeat annually 2, 5.
• Technique for hemophilia:
  • 23–25G needle; deltoid; apply firm pressure ≥2 minutes; time near factor/emicizumab dose.
• Document vaccine lot, site, and provide VIS.